Diagnostic Sensitivity
Sensitivity and Accuracy of Different Diagnostic Approaches for Monoclonal Proteins
Freelite® plus SPEP detects >99% of myelomas.
.jpg)
The NCCN and International Myeloma Working Group guidelines recommend use of serum free light chain assays in the initial diagnostic workup for multiple myeloma and related disorders.6-7 The use of free light chain assays along with SPEP and FLC provides a simple and efficient initial diagnostic screen for high tumor burden monoclonal gammopathies such as MM, WM, and SMM. Urine studies and serum IPE can be ordered more selectively.1
- Katzmann JA, et al. Screening panels for detection for monoclonal gammopathies. Clin Chem 2009; 55:1517-1522
- Lachmann HJ, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122:78-85
- Abraham RS et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002; 48:655-667
- Bradwell AR, et. al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361:489-491
- Drayson M, et. al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97:2900-2902
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.1.2012. © 2011 National Comprehensive Cancer Network, Inc. All rights reserved.
- Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23:215-224
